Xenon Pharmaceuticals Inc.
XENE
$55.23
-$2.67-4.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 13.81% | 2.76% | |||
| Gross Profit | -13.81% | -2.76% | |||
| SG&A Expenses | 14.45% | 0.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.94% | 2.24% | |||
| Operating Income | -13.94% | -2.24% | |||
| Income Before Tax | -16.08% | -5.73% | |||
| Income Tax Expenses | -20.53% | 208.15% | |||
| Earnings from Continuing Operations | -15.80% | -7.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.80% | -7.31% | |||
| EBIT | -13.94% | -2.24% | |||
| EBITDA | -14.07% | -2.24% | |||
| EPS Basic | -14.53% | -6.91% | |||
| Normalized Basic EPS | -14.81% | -5.33% | |||
| EPS Diluted | -14.53% | -6.91% | |||
| Normalized Diluted EPS | -14.81% | -5.33% | |||
| Average Basic Shares Outstanding | 1.11% | 0.37% | |||
| Average Diluted Shares Outstanding | 1.11% | 0.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||